Literature DB >> 30569390

Gallic and vanillic acid suppress inflammation and promote myelination in an in vitro mouse model of neurodegeneration.

Sonia Siddiqui1,2, Aisha Kamal3, Faisal Khan3, Khawar Saeed Jamali4, Zafar Saeed Saify5.   

Abstract

Neuroinflammation affects millions of people around the world as a result of injury or stress. Neuroinflammation represents almost all types of neurological diseases such as multiple sclerosis and Alzheimer's disease. Neurodegenerative diseases comprise demyelination and synaptic loss. The inflammatory response is further propagated by the activation of glial cells and modulation of constitutively expressed extracellular matrix proteins. The aim of the present study was to identify the anti-inflammatory effects of purified compounds gallic acid (GA, 1.0 µM) and vanillic acid (VA, 0.2 µM) on the lysolecithin (LPC, 0.003%)-induced model of inflammation. Hippocampal neurons were co-cultured with glial cells, and LPC was added to induce inflammation. Neurite outgrowth was measured by morphometry software. The level of myelination and demyelination was identified by immunostaining and sodium dodecyl sulfate polyacrylamide gel electrophoresis and western blotting techniques using different antibodies. Whole-cell patch clamp recordings were used to observe the sustained repetitive firing pattern. The data showed that GA and VA significantly increased the neurite outgrowth after 48 h in culture. Both compounds significantly reduced the expression of cyclooxygenase-2, NFκB, tenascin-C, chondroitin sulfate proteoglycans and glial fibrillary acidic protein in astrocytes in the LPC-induced model of inflammation. The level of myelin protein in neurites and oligodendrocyte cell bodies was significantly upregulated by GA and VA treatment. The reduction in sustained repetitive firing in the LPC-induced model of inflammation was reversed by both GA and VA treatment. This study supports the hypothesis that VA and GA have anti-inflammatory activities and could be regarded as potential treatments for neurodegenerative disease.

Entities:  

Keywords:  CNS injury; ECM proteins; GA; Lysolecithin; Remyelination; VA

Mesh:

Substances:

Year:  2018        PMID: 30569390     DOI: 10.1007/s11033-018-4557-1

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  7 in total

Review 1.  Anthocyanins and Their Metabolites as Therapeutic Agents for Neurodegenerative Disease.

Authors:  Aimee N Winter; Paula C Bickford
Journal:  Antioxidants (Basel)       Date:  2019-08-22

Review 2.  Anti-Inflammatory Medicinal Plants of Bangladesh-A Pharmacological Evaluation.

Authors:  Most Afia Akhtar
Journal:  Front Pharmacol       Date:  2022-03-24       Impact factor: 5.810

Review 3.  The Role of Extracellular Matrix in Human Neurodegenerative Diseases.

Authors:  Panka Pintér; Alán Alpár
Journal:  Int J Mol Sci       Date:  2022-09-21       Impact factor: 6.208

4.  He-Ne Laser Seed Treatment Improves the Nutraceutical Metabolic Pool of Sunflowers and Provides Better Tolerance Against Water Deficit.

Authors:  Saqib Mahmood; Beenish Afzal; Shagufta Perveen; Abdul Wahid; Muhammad Azeem; Naeem Iqbal
Journal:  Front Plant Sci       Date:  2021-05-17       Impact factor: 5.753

5.  Gallic Acid Prevents the Oxidative and Endoplasmic Reticulum Stresses in the Hippocampus of Adult-Onset Hypothyroid Rats.

Authors:  Vanessa Blas-Valdivia; Margarita Franco-Colín; Placido Rojas-Franco; Alberto Chao-Vazquez; Edgar Cano-Europa
Journal:  Front Pharmacol       Date:  2021-07-06       Impact factor: 5.810

Review 6.  Microbial Metabolites of Flavan-3-Ols and Their Biological Activity.

Authors:  Estefanía Márquez Campos; Peter Stehle; Marie-Christine Simon
Journal:  Nutrients       Date:  2019-09-20       Impact factor: 5.717

Review 7.  The Anti-Neuroinflammatory Role of Anthocyanins and Their Metabolites for the Prevention and Treatment of Brain Disorders.

Authors:  Joana F Henriques; Diana Serra; Teresa C P Dinis; Leonor M Almeida
Journal:  Int J Mol Sci       Date:  2020-11-17       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.